Latest Axoltis News & Updates

See the latest news and media coverage for Axoltis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Axoltis

Biopharmaceutical company developing neurological disease treatments

axoltis.com

Headquarters: Lyon, France
Company type: Private company
Number of employees: 15–50
Industry: Pharmaceuticals

Last updated Today

Latest news about Axoltis

In short: Axoltis shared Phase 2 results for NX210c in ALS, which showed reduced functional decline despite missing the trial's primary endpoint.

Company announcements

Yesterday Axoltis

Axoltis Pharma announces Phase 2 results for NX210c in ALS

Topline data shows reduced functional decline and target engagement, supporting continued clinical development.

June 24 Axoltis

Axoltis presents preliminary Phase 2 results for NX210c in ALS

The SEALS trial showed NX210c has a good safety profile and suggests efficacy signals in ALS patients at week 6.

January 30 Axoltis

Axoltis announces NX210c study publication

The study, partnered with InSilicoTrials, shows encouraging results for relapsing-remitting multiple sclerosis. It leverages modeling tools for R&D in neurodegenerative diseases.

January 13 Axoltis

Axoltis announces DSMB confirms NX210c safety

The second review of the SEALS Phase 2 ALS trial shows satisfactory safety and tolerability in the first 50 patients. Topline results expected Q2 2026.

Media coverage

Yesterday Yahoo

Axoltis' Phase II ALS trial fails; company points to exploratory endpoints

The ALS development space has been notoriously difficult for companies to navigate, with only three disease-modifying therapies currently FDA approved.

17 December 2025 Le Monde du Droit

Fairlight accompanies Norfoalk in the context of its reinvestment in the capital of the company Axoltis Pharma

Fairlight accompanies Norfoalk in the context of its reinvestment in the capital of the company Axoltis Pharma alongside the other historical shareholders and new...

3 December 2025 Fusacq

AXOLTIS PHARMA raises 18 M€ to accelerate the development of its drug candidate

Axoltis Pharma, a biotechnology company specialized in the development of innovative treatments against neurodegenerative diseases, announces the closing of a new funding round of...

1 December 2025 The Pharma Letter

Axoltis Pharma raises 18 million euros

Axoltis Pharma, a French biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announced the closing of an 18 million euros ($20.9...

Never miss news about Axoltis

Track Axoltis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Axoltis competitors & trending companies

Browse news for competitors to Axoltis and other trending companies.